What Klacid UNO treats: main uses and benefits

Klacid UNO is an antibiotic containing the active substance clarithromycin in a modified-release formulation. It belongs to the macrolide class of antibiotics and is designed to eliminate specific types of bacteria that cause infections in various parts of the body.

Primary Indications

This medication is primarily used to treat bacterial infections in the respiratory tract and skin. Its clinical applications include:

• Lower Respiratory Tract Infections: This includes conditions such as acute and chronic bronchitis, as well as pneumonia (including community-acquired pneumonia).
• Upper Respiratory Tract Infections: It is used for infections affecting the throat and nasal passages, such as pharyngitis, tonsillitis, and sinusitis.
• Skin and Soft Tissue Infections: It is indicated for mild to moderate infections of the skin, such as folliculitis, cellulitis, or erysipelas.

Mechanism of Action

Clarithromycin works by interfering with the protein synthesis of susceptible bacteria. By binding to the bacterial ribosome, it prevents the bacteria from producing essential proteins required for their growth and multiplication. This action either kills the bacteria or stops their spread, allowing the body's immune system to clear the infection.

Benefits of the Modified-Release Formulation

The "UNO" designation refers to the modified-release (extended-release) nature of the tablet. This formulation is designed to release the active ingredient slowly as it passes through the digestive system. Key characteristics of this format include:

• Sustained Concentration: It maintains a steady level of the medication in the bloodstream over a 24-hour period.
• Convenience: The extended-release profile typically allows for once-daily administration, which may support adherence to the full course of treatment.
• Targeted Delivery: The medication is absorbed consistently, ensuring that the antibiotic reaches the site of infection effectively throughout the day.

Regulatory References

1. NIH MedlinePlus overview on Clarithromycin

Who can and cannot use Klacid UNO?

Klacid UNO (Clarithromycin Modified-Release) eligibility is strictly defined by regulatory guidelines to ensure appropriate use. The medicine is contraindicated and must not be used in specific patient populations.

---

Absolute Contraindications

Absolute exclusions include individuals with known hypersensitivity to clarithromycin or any macrolide antibiotic. Contraindications also apply to patients with a history of heart rhythm disorders such as QT prolongation or ventricular arrhythmia, and those with uncorrected low potassium or magnesium levels. Furthermore, the drug is contraindicated in patients with severe hepatic failure combined with renal impairment.

Formulation and Age Restrictions

This specific modified-release formulation is contraindicated in patients with severe renal impairment (creatinine clearance less than 30 mL/min), due to the inability to split the tablet for dose reduction. Use of Klacid UNO is not recommended for children under 12 years of age.

Physiological Status

For physiological states, the medicine is not recommended during pregnancy (especially the first trimester) or while breastfeeding, unless official documentation notes no suitable alternative therapy. Caution is also advised for older adults and those with pre-existing cardiac or liver conditions.

Klacid UNO (clarithromycin) is a potent inhibitor of the Cytochrome P450 enzyme system, specifically CYP3A4, which can significantly alter the concentration and effects of many other medications. It is essential to inform your healthcare provider about all prescription drugs, over-the-counter medicines, and herbal supplements you are taking.

Contraindicated Combinations

The co-administration of Klacid UNO with certain medicines is strictly prohibited due to the potential for severe, life-threatening effects, including cardiac arrhythmias (QT prolongation) or rhabdomyolysis. These include:

Drug Type	Examples
HMG-CoA Reductase Inhibitors (Statins)	Simvastatin, Lovastatin
Ergot Alkaloids (Migraine)	Ergotamine, Dihydroergotamine
Antihistamines	Terfenadine, Astemizole
Motility Agents	Cisapride, Domperidone
Antipsychotics	Pimozide

Caution and Dose Adjustment

Increased monitoring or dose adjustments are typically required when Klacid UNO is taken with the following types of medicines, as their effects may be enhanced:

• Anticoagulants (e.g., Warfarin, Rivaroxaban): Increased risk of bleeding. Close monitoring of blood clotting indices is necessary.
• Colchicine (for gout): Increased risk of colchicine toxicity, especially in patients with kidney or liver impairment.
• Digoxin (for heart failure): Increased serum levels of digoxin.
• Benzodiazepines (e.g., Midazolam, Triazolam):
• Anticonvulsants (e.g., Carbamazepine, Phenytoin)
• Medicines for heart rhythm (e.g., Quinidine, Disopyramide)

Conversely, drugs that induce (increase the activity of) CYP3A4, such as Rifampicin, Carbamazepine, and Phenytoin, may decrease the concentration of clarithromycin, potentially leading to reduced effectiveness of Klacid UNO.

Klacid UNO contains clarithromycin, a macrolide antimicrobial, which acts as a protein synthesis inhibitor within susceptible prokaryotic cells. The drug and its primary active metabolite, 14-hydroxyclarithromycin, achieve selective accumulation within target cells and tissues, including phagocytes.

Its biological target is the 23S ribosomal RNA of the 50S ribosomal subunit of the bacterium. Clarithromycin forms a non-covalent interaction, binding reversibly to the P-site and A-site tunnel entrance. This binding event blocks the nascent polypeptide chain from elongating, inhibiting the peptidyl transferase reaction and interfering with the translocation of aminoacyl-transfer RNA.

The resulting molecular blockade prevents the assembly of essential proteins, which immediately leads to an intracellular arrest of translation. This cascade culminates in a system-level physiological consequence of modulating the microbial population load by preventing cellular proliferation and survival, leading to a sustained reduction in the density of susceptible microorganisms.

Official Administration Guidelines

Klacid UNO is a modified-release tablet form of clarithromycin, designed to function within the constraints of its sustained-release delivery system.

---

Administration Scope

Instruction	Official Administration Detail
Route of Administration	Oral administration only.
Standard Dosing Regimen	The standard adult dose is typically 1000 mg per day, which corresponds to two 500 mg tablets. The course duration is generally short-term, ranging from 7 to 14 days.
Frequency and Timing	Administration is restricted to once daily (every 24 hours), leveraging the extended-release technology.
Intake Condition	The tablets must be taken with food to ensure optimal drug absorption and performance of the sustained-release mechanism.

---

Procedural Constraints and Adjustments

The proper use of Klacid UNO requires adherence to physical and population-specific guidelines.

Procedural Requirement	Requirement Detail
Tablet Integrity	The tablets must be swallowed whole and must not be chewed, broken, or crushed.
Population Rule	The extended-release form is not recommended for use in children younger than 12 years of age.
Renal Adjustment	A dose reduction of 50% is required for patients with severe renal impairment (creatinine clearance le 30 mL/min), reflecting the body’s reduced ability to clear the drug.

If a dose is missed, the dose should be taken as soon as it is remembered, unless the next dose is due shortly. It is explicitly instructed not to double the dose to compensate for a missed one. This procedural structure is necessary to ensure the drug is released consistently over 24 hours and maintains therapeutic concentration.

Recent Clinical Evidence Summary

Mechanism of Action and Formulation

Studies have explored the drug's potential by examining its effect on neurotransmitter availability, consistent with its classification as a macrolide antibiotic that inhibits bacterial protein synthesis. Klacid UNO is the extended-release (ER) formulation of clarithromycin. Research in pharmacokinetics has investigated the drug's absorption, including how it is processed and eliminated from the body. Studies have shown that the ER formulation maintains drug concentrations over a prolonged period compared to immediate-release formulations.

---

Efficacy in Respiratory and Skin Infections

Clinical studies, including randomized controlled trials, have evaluated the drug for use in both chronic and acute conditions, such as upper and lower respiratory tract infections and skin structure infections. A key meta-analysis reported that studies examined the drug for short-term symptom relief in a high percentage of study participants across various infection types. Comparative trials have explored the use of the ER formulation against other standard antibiotics, particularly in conditions like pharyngitis and acute bacterial exacerbations of chronic bronchitis.

---

Safety and Long-Term Outcomes

The scope of long-term studies (up to 12 months) has included the monitoring of delayed or long-term effects. Research has explored whether participants in studies reported continued symptom changes and improvements in quality of life scores. Studies exploring the use of the drug have excluded participants with severe heart disease, and research is ongoing to further characterize potential cardiovascular events. Regulatory bodies have advised caution when prescribing clarithromycin to patients with underlying heart conditions due to limited evidence suggesting a potential for increased long-term cardiac risks in this population.

Key Studies & References Clarithromycin: overview and its current clinical utility in the treatment of respiratory tract infections

Common questions about Klacid UNO (FAQ)

Q: What type of infections is Klacid UNO typically used for?

According to the official product information, Klacid UNO is officially indicated for conditions caused by susceptible bacterial infections. These typically include infections in the upper and lower respiratory tracts, such as pharyngitis, sinusitis, bronchitis, and pneumonia. It is also documented for use in specific infections of the skin and soft tissue.

---

Q: How does Klacid UNO differ from standard Klacid tablets?

Klacid UNO is the modified-release formulation of the active ingredient, clarithromycin. Its sustained-release design means that the medicine is slowly dispersed over time. This technological difference is associated with a once-daily administration regimen, unlike standard immediate-release forms.

---

Q: Is Klacid UNO the same as erythromycin or azithromycin?

Klacid UNO contains the active ingredient clarithromycin, which is classified as a macrolide antibiotic. It is a derivative of erythromycin, an older drug in the same class. Although it shares the same class as azithromycin, clarithromycin is a distinct compound with its own specific properties and documented indications.

---

Q: What foods or drinks should be avoided while taking Klacid UNO?

Official administration guidelines state the tablet is to be taken with food to ensure the proper functioning of the extended-release mechanism. The product’s official labeling does not list a direct contraindication for alcohol or most common foods and drinks. Information on diet or alcohol consumption during treatment should be verified against official product documentation.

---

Q: Why are people sometimes prescribed Klacid UNO instead of another antibiotic?

Klacid UNO is often selected by healthcare professionals due to its extended-release design. This formulation is designed to maintain consistent therapeutic levels of the antibiotic in the body over a 24-hour period. This sustained level of the drug is associated with the convenience of once-daily administration.

---

Q: What should I do if I notice a skin rash after starting Klacid UNO?

Regulatory documents classify a general rash as a common side effect of this medicine. However, official safety information also documents the risk of rare, severe cutaneous reactions, such as Stevens-Johnson Syndrome. If any severe reaction occurs, including blistering, peeling skin, or swelling, the need for immediate medical review is documented.

---

Q: Does the time of day matter when taking Klacid UNO?

Administration guidelines require the tablet be taken with food once daily (every 24 hours). The specific time of day is not stated as critical in regulatory information. Maintaining a consistent 24-hour interval is a key requirement to support the sustained-release mechanism.

---

Q: Are there different strengths of Klacid UNO available?

The official prescribing information indicates that the extended-release formulation of Klacid UNO is available in a 500 mg tablet strength. The medicine is generally prescribed in amounts that meet the documented therapeutic concentration.

---

Q: What kind of infections are not treated by Klacid UNO?

As Klacid UNO is classified as an antibiotic, its purpose is to control bacterial infections. Therefore, it is described as not being effective against infections caused by viruses, such as the common cold or flu. Regulatory guidance emphasizes that the medicine is only to be used against organisms that are documented as being susceptible to clarithromycin.

---

Q: What are the signs of a serious allergic reaction to Klacid UNO?

Official safety warnings document the risk of severe acute hypersensitivity reactions, including anaphylaxis. Signs that are documented in official safety information include difficulty breathing, swelling of the face, lips, or throat, and severe skin reactions such as blistering or peeling. Immediate medical review is advised in the event of these signs.

---

Q: What are the official warnings about taking Klacid UNO?

Official safety documents contain multiple warnings and contraindications. These include cautions regarding the risk of serious cardiac effects (like QT prolongation), liver dysfunction, and severe skin reactions. Furthermore, the medicine carries a strict contraindication for use with certain drugs, such as simvastatin, lovastatin, and ergot alkaloids.

---

Q: Can Klacid UNO be used for viral infections like the common cold?

Klacid UNO is classified as a macrolide antibiotic, meaning its pharmacological action is directed only at managing bacterial growth. The medicine is documented as not being indicated for the treatment of viral illnesses, such as the common cold or influenza.

---

Q: Are there any known interactions between Klacid UNO and birth control pills?

Official regulatory interaction tables do not list oral contraceptives as a medicine that is contraindicated or requires specific dose adjustment due to a direct metabolic interaction. However, it is noted that severe gastrointestinal side effects, such as vomiting or severe diarrhea, are documented as potentially affecting the absorption of oral contraceptives.

---

Q: Does Klacid UNO interact with alcohol?

Official regulatory documents do not list a direct chemical interaction between Klacid UNO and alcohol that affects the efficacy of the medicine. Official labeling does not list a direct interaction; however, health authorities often advise against alcohol consumption during recovery from an infection.

---

Q: Can Klacid UNO be taken with antacids?

Regulatory cautions advise that taking Klacid UNO at the same time as antacids that contain aluminum, or with citrates, is cautioned against by regulatory sources. This combination may lead to increased aluminum levels, especially in patients with reduced kidney function.

---

Q: What pain relievers, if any, can be taken with Klacid UNO?

Official interaction documents do not list common over-the-counter pain relievers, such as ibuprofen or paracetamol, as medicines that are prohibited or require a specific dose adjustment due to a direct metabolic interaction.

---

Q: Is it normal to feel tired while taking Klacid UNO?

General tiredness or fatigue is not explicitly listed as a common side effect in the official regulatory documents. However, official safety information does document other central nervous system effects such as headache, dizziness, and insomnia (difficulty sleeping).

---

Q: Is Klacid UNO effective against Helicobacter pylori?

Yes, the active ingredient in Klacid UNO, clarithromycin, is documented for use in combination therapy for the eradication of Helicobacter pylori in patients with duodenal ulcers. This use is specifically indicated as part of a combination regimen.

---

Q: Does Klacid UNO affect blood sugar levels?

Regulatory information notes that Klacid UNO may potentially cause hypoglycemia, which is low blood sugar. This effect is specifically documented as a caution when the medicine is used in combination with certain oral anti-diabetic medications.

---

Q: Can I drive or operate machinery while taking Klacid UNO?

Official warnings advise caution regarding the ability to drive or operate heavy machinery while taking Klacid UNO. This advice is provided because the medicine has been associated with central nervous system effects like dizziness, disorientation, and loss of balance.

---

Q: What is the risk of antibiotic resistance with Klacid UNO?

Official guidance for antibacterial agents notes that the use of any antibiotic, including Klacid UNO, carries a risk of selecting for drug-resistant organisms. This is noted as a necessary consideration related to the long-term effectiveness of antimicrobial treatment.

---

Q: Can Klacid UNO make me sensitive to sunlight?

Regulatory documents list photophobia (sensitivity to light) as an uncommon adverse reaction associated with the use of clarithromycin. This involves an increased sensitivity of the eyes to light.

---

Q: Why is it important to complete the entire course of Klacid UNO?

Official guidance emphasizes that completing the entire duration of the prescribed course is a measure intended to maximize the potential treatment benefit. Adherence to the full course also helps to manage the risk of promoting drug-resistant organisms.

---

Q: Does taking Klacid UNO cause yeast infections?

Regulatory information notes that taking this antibiotic may pose a risk of developing fungal infections, specifically oral or vaginal candidiasis (commonly known as yeast infections). This occurrence is associated with the medicine potentially eliminating the body’s natural bacterial competitors that help control fungal growth.

---

Q: Does the tablet coating of Klacid UNO have a specific purpose?

Yes, Klacid UNO is a modified-release tablet, and its physical design is specialized. The structure and coatings are engineered to ensure the active ingredient is dispersed slowly and steadily over an extended period. This is the mechanism that enables the once-daily administration.

The storage and disposal of Klacid UNO (clarithromycin extended-release) must strictly follow conditions defined by regulatory authorities.

Storage Requirements

Condition	Requirement	Constraint
Temperature	Store at Controlled Room Temperature (20 C to 25 C)	Do not freeze; avoid excessive heat
Container	Keep in the container it came in, tightly closed	Protect from light and moisture
Safety	Must be kept out of the reach of children

Disposal Instructions

Disposal of unused or expired tablets should prioritize authorized drug take-back programs. If a take-back program is unavailable, the medicine is not suitable for flushing and must be disposed of with household trash. This requires mixing the tablets with an undesirable substance, such as dirt or used coffee grounds, and placing the mixture in a sealed container before discarding. All personal information should be removed from the original packaging prior to disposal.